Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three se... Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three segments: North America, Europe and International Markets. Each business segment manages a product portfolio in its region, including generics, which include biosimilars and over-the-counter products, as well as innovative medicines. 詳細を表示
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms...
IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying...
Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscienceData show TEV-'749 drug delivery...
Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupportedThe company intends...
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia...
The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024The collaboration supports Teva's Pivot to Growth strategy and...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.58 | -3.33525014376 | 17.39 | 17.5 | 16.15 | 7580492 | 16.71638274 | DR |
4 | -1.3236 | -7.29915736533 | 18.1336 | 19.31 | 16.15 | 7151558 | 17.66417027 | DR |
12 | -1.73 | -9.33117583603 | 18.54 | 19.31 | 16.15 | 6602207 | 17.86430007 | DR |
26 | 0.36 | 2.18844984802 | 16.45 | 19.31 | 15.62 | 7817494 | 17.33180907 | DR |
52 | 7.75 | 85.5408388521 | 9.06 | 19.31 | 9.04 | 9025675 | 14.73009105 | DR |
156 | 7.91 | 88.8764044944 | 8.9 | 19.31 | 6.7791 | 9894250 | 10.58862558 | DR |
260 | 6.23 | 58.8846880907 | 10.58 | 19.31 | 6.25 | 10429693 | 10.47769577 | DR |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約